New Delhi: All India Institute of Medical Sciences (AIIMS), Patna has began paediatric trials of Bharat Biotech’s Covaxin.
Bharat Biotech acquired the Drugs Controller General of India (DCGI) nod to conduct scientific trials of its COVID-19 vaccine on children in May.
VK Paul, Member (Health), Niti Aayog had knowledgeable, “Covaxin has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years.”
Covaxin is India’s indigenous COVID-19 vaccine manufactured by Bharat Biotech, developed in collaboration with the Indian Council of Medical Research (ICMR).
India has given approval to 3 COVID-19 vaccines – Bharat Biotech`s Covaxin, Serum Institute of India’s Covishield and Russia`s Sputnik V.
Meanwhile, the Centre on Tuesday (June 1) warned that COVID-19 can have an elevated influence on children if the virus modifications conduct.
“COVID-19 in children is often asymptomatic and rarely requires hospitalization. However, changes in epidemiological dynamics or viral behaviour can change the situation and increase the prevalence of infection. No undue burden has been placed on the paediatric care infrastructure so far. However, it is possible that 2-3 percent of children who get infected may need hospitalization,” Paul had mentioned.
He added {that a} nationwide knowledgeable group has been shaped who’ve created pointers to deal with COVID-19 in children, which can be publicly launched quickly.
(With inputs from companies)
